Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hip Arthritis Clear all
Completed Phase 2 Interventional

A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee

NCT02524197
View directory record Official record
Conditions
Osteoarthritis
Interventions
CR845 0.25 mg, CR845 0.50 mg, CR845 1 mg, CR845 5 mg
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
25 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Omaha, Nebraska • Las Vegas, Nevada • Greensboro, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Sep 25, 2026, 4:14 AM EDT
Enrolling by invitation Not applicable Interventional

Rate of Allergic Contact Dermatitis and Cosmetic Outcomes

NCT06957444
View directory record Official record
Conditions
Allergic Contact Dermatitis, Osteoarthritis, Hip, Osteoarthritis, Knee
Interventions
Sylke Adhesive Dressing, Exofin Skin Glue, Suture Strip Plus
Procedure
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 25, 2026, 4:14 AM EDT
Completed Phase 2Phase 3 Interventional

Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip

NCT02447276
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
REGN475, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
72
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 25, 2026, 4:14 AM EDT
Withdrawn Not applicable Interventional

Leisure Expectations About Physical Activity Study

NCT01938274
View directory record Official record
Conditions
Hip Osteoarthritis, Knee Osteoarthritis
Interventions
Educational intervention
Other
Lead sponsor
West Virginia University
Other
Eligibility
45 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Sep 25, 2026, 4:14 AM EDT
Completed Not applicable Interventional

Vivacit-E Post-market Follow-up Study

NCT03226808
View directory record Official record
Conditions
Osteoarthritis, Avascular Necrosis of Bone of Hip, Post-traumatic; Arthrosis, Congenital Hip Dysplasia
Interventions
Vivacit-E Liner
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years to 60 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
5
States / cities
Parker, Colorado • Chapel Hill, North Carolina • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 25, 2026, 4:14 AM EDT
Not yet recruiting Not applicable Interventional

Psychosocial Interventions for Young Adults With Hip Pain

NCT04039386
View directory record Official record
Conditions
Hip Dysplasia, Hip Pain Chronic, Hip Osteoarthritis, Hip Arthritis, Psychosocial Problem
Interventions
Cell Phone Based Cognitive Based Therapy (Pacifica App), Control
Device · Other
Lead sponsor
Michael C Willey
Other
Eligibility
15 Years to 39 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 25, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee

NCT03691974
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Fasinumab, Placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
21
States / cities
Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Sep 25, 2026, 4:14 AM EDT
Recruiting No phase listed Observational

Perfusion MRI-targeted Joint Embolization for Chronic Musculoskeletal Pain of the Shoulder, Hip and Knee

NCT05700682
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip, Osteo Arthritis Shoulders, Synovitis of Knee, Synovitis/Tenosynovitis - Hip, Synovitis, Pain, Chronic
Interventions
Shoulder/Hip/Knee Embolization with Embozene Microspheres
Device
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
25 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 25, 2026, 4:14 AM EDT
Terminated No phase listed Observational

A Multi-centre, Prospective Surveillance to Assess Mid-term Performance of the Mpact Cup

NCT02196818
View directory record Official record
Conditions
Osteoarthritis, Arthritis, Avascular Necrosis, Fracture of the Femoral Neck or Head, Congenital Hip Dysplasia
Interventions
Mpact Acetabular Shell
Device
Lead sponsor
Medacta International SA
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
4
States / cities
Denver, Colorado • Boise, Idaho • Libertyville, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Sep 25, 2026, 4:14 AM EDT
Terminated Not applicable Interventional Results available

Clinical Study Comparing Two Implant Surface Finishes in Patients Undergoing Cementless Total Hip Replacement

NCT00306917
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Post-traumatic Arthritis, Avascular Necrosis, Acute Fracture
Interventions
non-coated femoral hip stem, coated femoral hip stem
Device
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
Up to 75 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Warsaw, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Sep 25, 2026, 4:14 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis

NCT03793010
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
FX006, Normal saline
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Canoga Park, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Sep 25, 2026, 4:14 AM EDT
Completed Phase 3 Interventional

Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003

NCT02289716
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Placebo, Fulranumab 1 mg, Fulranumab 3 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
El Cajon, California • Sherman Oaks, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 25, 2026, 4:14 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

ROSA® Hip System THA PMCF

NCT05497206
View directory record Official record
Conditions
Osteoarthritis, Hip, Avascular Necrosis of Hip
Interventions
One of the following hip implants may be used within this arm of the study: G7 Acetabular System, Taperloc Complete System, Avenir and Avenir Complete Systems, and Echo Bi-Metric System
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Jacksonville, Florida • Saint Joseph, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Sep 25, 2026, 4:14 AM EDT
Recruiting Not applicable Interventional

Outcomes of Low-Impact Exercise Program for People With Ankle, Knee, and/or Hip Pain

NCT03711773
View directory record Official record
Conditions
Osteoarthritis, Osteoarthritis, Knee, Osteoarthritis, Hip, Osteoarthritis Ankle
Interventions
Group Physical Therapy Classes
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 25, 2026, 4:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Incorporating Patient-Reported Outcomes Into Shared Decision Making With Patients With Osteoarthritis of the Hip or Knee

NCT04805554
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Joint Insights decision aid
Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
45 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 25, 2026, 4:14 AM EDT
Not listed Phase 1 Interventional

A Comparison of PRP Treatment to the IA vs. IA and EA Environments in Patients Diagnosed With Hip Osteoarthritis

NCT04241354
View directory record Official record
Conditions
Osteoarthritis, Hip, Osteoarthritis, Degeneration
Interventions
Leukocyte-poor platelet rich plasma
Biological
Lead sponsor
Regenerative Orthopedics and Sports Medicine
Industry
Eligibility
30 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
North Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Sep 25, 2026, 4:14 AM EDT
Terminated Phase 2 Interventional Results available

A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections

NCT00994890
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Tanezumab 2.5 mg, Tanezumab 5 mg, Tanezumab 10 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
100
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 25, 2026, 4:14 AM EDT
Active, not recruiting Phase 1 Interventional

Autologous Culture Expanded Adipose Derived MSCs for Treatment of Painful Hip OA

NCT03608579
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Autologous Adipose Derived Mesenchymal Stromal Cells
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Sep 25, 2026, 4:14 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Clinical Outcome and Fusion Results Using the SiJoin® Transfixing Sacroiliac Fusion Device

NCT05712850
View directory record Official record
Conditions
Sacroiliitis, Sacroiliac Joint Dysfunction, Iatrogenic Injury, Osteitis Condensans Ilii, Pelvic Fracture
Interventions
SiJoin® Transfixing Sacroiliac Fusion Device
Procedure
Lead sponsor
VG Innovations, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Naples, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 25, 2026, 4:14 AM EDT
Completed Phase 4 Interventional Results available

Fascia Iliaca Blocks for Pain Control After Total Hip Arthroplasty

NCT03375112
View directory record Official record
Conditions
Arthritis of Hip
Interventions
Fascia iliaca compartment block, Placebo, Bupivacaine
Procedure · Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 25, 2026, 4:14 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip

NCT03949673
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Fasinumab, Naproxen, Diclofenac, Celecoxib, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Phoenix, Arizona • Littleton, Colorado • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Sep 25, 2026, 4:14 AM EDT
Not listed Not applicable Interventional

Use of Cooled Radiofrequency for the Treatment of Hip Pain Associated With Hip OA Compared to Intra-articular Steroid Injections

NCT04329884
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Cooled RFA treatment with COOLIEF* device, intra-articular corticosteroid injection
Procedure · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Sep 25, 2026, 4:14 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Non-invasive Evaluation of Upper and Lower Body Function With Showmotion

NCT04137835
View directory record Official record
Conditions
Osteoarthritis, Hip, Osteoarthritis, Knee, Osteoarthritis, Spine
Interventions
Showmotion
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Sep 25, 2026, 4:14 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee

NCT00313846
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 75 Years
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
44
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Sep 25, 2026, 4:14 AM EDT